Ceftriaxone

Generic Name: Ceftriaxone

Brand Names: Rocephin

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₈N_₈O_₇S_₃

CAS Number: 73384-59-5

Unique Ingredient Identifier: 75J73V1629

Background: Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.

Indication: Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.

Associated Conditions: Abscess Brain, Bacterial Endocarditis, Bacterial Infections, Bacterial Sinusitis, Bone and Joint Infections, Chancroid, Community Acquired Pneumonia (CAP), Conjunctivitis gonococcal neonatal, Epididymitis, Epiglottitis, Gonococcal arthritis, Gonococcal infection of pharynx, Gonococcal pelvic inflammatory disease, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lyme Neuroborreliosis, Meningitis, Bacterial, Ophthalmia neonatorum due to gonococcus, Postoperative Infections, Prosthetic Joint Infections, Sepsis Bacterial, Septic Arthritis, Shigellosis, Skin and Subcutaneous Tissue Bacterial Infections, Syphilis, Vulvovaginitis gonococcal, Whipple Disease, Bacterial otitis media, Complicated Urinary Tract Infection caused by susceptible bacteria, Disease caused by Salmonella typhi, Susceptible Bacterial Infections, Uncomplicated Gonorrhea, Uncomplicated Urinary tract infection bacterial

Clinical Trials

Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition

Phase 2

Conditions: HIV-1-infection
Malnutrition, Child

Interventions: Drug: Ampicillin
Drug: Ceftriaxone Sodium
Drug: Gentamicin

First Posted Date: 2021-09-21

Last Posted Date: 2021-09-30

Lead Sponsor: Makerere University

Target Recruit Count: 300

Registration Number: NCT05051163

Locations: 🇺🇬
Makerere University College of Health Sciences, Kampala, Central, Uganda

Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea

Phase 4

Completed

Conditions: Neisseria Gonorrhoeae

Interventions: Drug: Rocephin
Drug: Azithromycin

First Posted Date: 2021-08-30

Last Posted Date: 2024-08-02

Lead Sponsor: Institute of Tropical Medicine, Belgium

Target Recruit Count: 42

Registration Number: NCT05027516

Locations: 🇧🇪
Institute of Tropical Medicine, Antwerpen, Belgium

Assessing Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration for Prevention of SSI

Phase 4

Withdrawn

Conditions: Surgical Wound Infection
Surgical Site Infection

Interventions: Drug: Ceftriaxone Sodium

First Posted Date: 2021-07-26

Last Posted Date: 2025-03-25

Lead Sponsor: The Grant Medical College & Sir J.J. Group of Hospitals

Target Recruit Count: 250

Registration Number: NCT04975945

Locations: 🇮🇳
Grant Government Medical College and Sir JJ Hospital, Mumbai, Maharashtra, India

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

Phase 1

Completed

Conditions: Gonococcal Infection

Interventions: Drug: Azithromycin
Drug: Ceftriaxone
Drug: Ciprofloxacin
Biological: Neisseria gonorrhoeae strain FA1090 A26
Biological: Neisseria gonorrhoeae strain FA7527

First Posted Date: 2021-05-03

Last Posted Date: 2021-12-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT04870138

Locations: 🇺🇸
University of North Carolina Health Care - Infectious Diseases, Chapel Hill, North Carolina, United States

Prophylactic Antibiotics in Admitted Cirrhotics

Phase 4

Completed

Conditions: Cirrhosis, Liver

Interventions: Drug: Normal saline
Drug: Ceftriaxone

First Posted Date: 2020-01-06

Last Posted Date: 2023-03-03

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 32

Registration Number: NCT04218695

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea

Phase 4

Completed

Conditions: Gonorrhea

Interventions: Drug: Ceftriaxone sodium and Sulbactam Sodium for injection

First Posted Date: 2019-12-17

Last Posted Date: 2019-12-17

Lead Sponsor: Xiangbei Welman Pharmaceutical Co., Ltd

Target Recruit Count: 113

Registration Number: NCT04202068

Ceftriaxone as Home IV for Staph Infections

Phase 4

Conditions: Staphylococcal Infections
Osteomyelitis
CNS Infection
Septic Arthritis
Diabetic Foot Infection
Vertebral Osteomyelitis
Abscess
Coagulase Negative Staphylococcal Infection